Medicine

New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

Terry Gernsheimer
Terry Gernsheimer

TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.

Download this interview

Similar Interviews

  • Live Report from ASH:
    Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
  • Richard Stone RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute New data shows

  • Audio Journal of Cardiovascular Medicine: Drug Eluting Stent Shows Great Benefit in Chronic Total Occlusions">Audio Journal of Cardiovascular Medicine: Drug Eluting Stent Shows Great Benefit in Chronic Total Occlusions
  • Gerald Werner REFERENCE: Abstract 925, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria

  • Audio Journal of Cardiovascular Medicine: September 8th 2006 - Reporting from the World Congress of Cardiology joint meeting with European Society of Cardiology, September 2-6, 2006, Barcelona">Audio Journal of Cardiovascular Medicine: September 8th 2006 - Reporting from the World Congress of Cardiology joint meeting with European Society of Cardiology, September 2-6, 2006, Barcelona
  • Christoph Kaiser
    1. Would the AMG 531 be something you would recommend to a young lady in childbearing ages wanting to persue fertility in hopes to become pregnant? Is this a better option than having the spleen removed?

      Posted by Kelli Tucker | April 24, 2008, 3:41 pm

    Post a comment